Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Activiomics Signs Research Agreement with Kyowa Hakko Kirin

Published: Friday, November 23, 2012
Last Updated: Friday, November 23, 2012
Bookmark and Share
Company signs agreement as part of its strategic partnership with BioFocus.

Activiomics has announced that it has signed a research agreement with the Japanese pharmaceutical company Kyowa Hakko Kirin.

Under the agreement, Activiomics will apply its novel TIQUAS phosphoproteomics platform to elucidate signalling mechanisms of lead compounds in relevant cell-based systems.

This agreement was signed as part of Activiomics’ recently announced strategic partnership with BioFocus.

Activiomics partners with Pharma and Biotech using its innovative mass spectrometry based methods to analyze and interpret cell signalling pathway activity, generating high value information for the pharmaceutical and biotechnology industry.

“We’ve engaged with Activiomics because we recognize that Activiomics’ label free phosphoproteomics approach can provide unique insights into signalling pathway activity, information that can complement and extend our existing gene expression datasets. This technology will enable us to better understand cell signalling mechanisms of our lead compounds and could enable us to identify important biomarkers” said Etsuo Ohshima, Ph.D., managing officer and vice president, head, research division at Kyowa Hakko Kirin.

Dr Neil Torbett, COO of Activiomics, said: “We are delighted to have signed this agreement with Kyowa Hakko Kirin. This is a further endorsement of our technology platform and also represents Activiomics’ first entry into the Japanese market. Activiomics has received invaluable support from BioFocus in establishing this collaboration, a clear demonstration of our strategic partnership in action”.

Dr Chris Newton, Managing Director of BioFocus, commented “BioFocus is pleased to have participated in the signing of this deal, which we intend to be the first of many. Future deals will add together BioFocus’ drug discovery capabilities and Activiomics’ phosphoproteomics platform for the furtherance of our clients’ projects”.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Activiomics Extends Agreement with Kyowa Hakko Kirin
Activiomics announced it has extended its Contract Research Agreement with Japanese pharmaceutical company Kyowa Hakko Kirin (KHK) by entering into a new research programme.
Thursday, September 19, 2013
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Could 2D Mass Spec Breakthrough Lead to Medical Revolution?
Pharmaceutical research could be quicker and more precise, thanks to an innovative breakthrough in 2D mass spec from the University of Warwick.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Reclaim from the Drain - The Importance of Water Reuse
This infographic explains the importance of reusing water to meet the world's increasing water demand.
Clinical Trial Finds Medicine Program Alters Blood Serum
Meditation, yoga and vegetarian diet linked to decline in plasma metabolites associated with inflammation and cardiovascular disease risk.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Antibiotic Resistance Can Occur Naturally in Soil Bacteria
Scientists have found natural anti-biotic resistant bacteria in soils with little to no human exposure.
Gene Deletion Reveals Cell Secrets
Researchers have deleted 174 genes in yeast to analyse the effect of individual gene deletion.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Impact of Emerging Contaminants in Our Water Supply
Emerging contaminants, any synthetic or naturally occurring chemical not commonly monitored in the environment, in our water supply are becoming of increasing concern due to their potential ecological and/or human health effects.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos